Table 7.
Prognostic tumor characteristics in patients according to their hormonal status (pre vs. postmenopausal).
| Variable | All patients n = 347 (100%) |
Premenopausal n = 108 (%) |
Postmenopausal n = 239 (%) |
p |
|---|---|---|---|---|
| Clinical tumor size (mm) | 22.63 ± 14.64 | 23.31 ± 13.87 | 22.32 ± 15.02 | 0.61 |
| Pathological tumor size (mm) | 24.23 ± 14.87 | 24.04 ± 12.43 | 24.20 ± 15.63 | 0.93 |
| Tumor size (cm) (n = 68) (a) | ||||
| ≤ 2 cm | 151 (57.85%) | 49 (59.04%) | 102 (57.30%) | 0.86 |
| > 2 cm | 110 (42.15%) | 34 (40.96%) | 76 (42.70%) | |
| Clinical stage | ||||
| I | 115 (41.22%) | 36 (39.56%) | 79 (42.02%) | 0.65 |
| II, III | 143 (51.25%) | 48 (52.75%) | 95 (50.53%) | |
| III | 21 (7.53%) | 7 (7.69%) | 14 (7.45%) | |
| Pathological stage | ||||
| Initial (I) | 111 (36.75%) | 33 (35.48%) | 78 (37.32%) | 0.95 |
| Intermediate (II, III) | 168 (55.93%) | 52 (55.91%) | 116 (55.50%) | |
| Advanced (IV) | 23 (7.62%) | 8 (8.61%) | 15 (7.18%) | |
| Axillary invasion (n = 48) | ||||
| Negative | 112 (39.44%) | 40 (44.94%) | 82 (40%) | 0.53 |
| Positive | 172 (60.56%) | 49 (55.06%) | 123 (60%) | |
| Histological type | ||||
| Ductal | 299 (95.22%) | 101 (97.12%) | 198 (94.29%) | 0.18 |
| Lobulillar | 15 (4.78%) | 3 (2.88%) | 12 (5.71%) | |
| Differentiation degree | ||||
| 1, 2 | 196 (71.01%) | 58 (67.44%) | 138 (72.63%) | 0.80 |
| 3 | 80 (28.99%) | 28 (32.56%) | 52 (27.37%) | |
| Lymphovascular invasion (a) | ||||
| Yes | 15 (6.38%) | 5 (7.35%) | 12 (7.10%) | 0.26 |
| No | 220 (93.62%) | 63 (92.65%) | 157 (92.9%) | |
| Ki-67 (a) | ||||
| (+) | 37 (13.55%) | 9 (10.59%) | 28 (14.89%) | 0.60 |
| (−) | 236 (86.45%) | 76 (89.41%) | 160 (85.11%) | |
| Ki-67 (%) (a) n(84) | 28.83 ± 12.11 | 28.74 ± 12.15 | 28.95 ± 13.14 | 0.94 |
| ER | ||||
| (+) | 269 (85.4%) | 80 (83.33%) | 189 (86.3%) | 0.56 |
| (−) | 46 (14.6%) | 16 (16.67%) | 30 (13.7%) | |
| PR | ||||
| (+) | 244 (77.96%) | 78 (81.25%) | 166 (76.5%) | 0.25 |
| (−) | 69 (22.04%) | 18 (18.75%) | 51 (23.50%) | |
| Cerb2 (a) | ||||
| (+) | 83 (29.12%) | 28 (32.56%) | 55 (27.64%) | 0.63 |
| (−) | 202 (70.88%) | 58 (67.44%) | 144 (72.36%) | |
| NPI | 3.71 ± 1.81 | 3.82 ± 1.76 | 3.59 ± 1.94 | 0.35 |
| NPI | ||||
| < 2 | 49 (16.78%) | 9 (10.11%) | 40 (19.7%) | 0.43 |
| 2–2.4 | 45 (15.51%) | 14 (15.73%) | 31 (15.27%) | |
| 2.4–3.4 | 58 (19.85%) | 22 (24.72%) | 36 (17.73%) | |
| 3.4–5.4 | 53 (18.15%) | 17 (19.10%) | 36 (17.73%) | |
| > 5.4 | 87 (29.79%) | 27 (30.34%) | 60 (29.56%) | |
Data expressed as means ± standard deviation and absolute numbers and their frequencies.
NPI Nottingham prognostic index.
*p value < 0.05 (t-Student or Chi-squared).
aAnalysis performed on the cases provided by the pathology department.